Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Treatment of acute lymphoblastic leukemia (ALL) is associated with neurocognitive deficits in young children. While computerized measures have been utilized in pediatric oncology research, they exclude patients below the age of 4 years. Patients enrolled on "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents" were offered participation in an optional neurocognitive study. Three-year old patients did not differ from 4-year-old patients in their ability to perform or complete the tests. Including patients diagnosed at age 3 will serve to improve our understanding of at-risk patients and their neurocognitive trajectory both during and after treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759646 | PMC |
| http://dx.doi.org/10.1002/pbc.31469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lineage Switch of Adult B-Cell Acute Lymphoblastic Leukaemia to Acute Myeloid Leukaemia Following B-Cell-Directed Therapy.
Eur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDFSuccessful remission induction therapy with azacitidine and venetoclax for a treatment-naive elderly patient with ETP/myeloid mixed-phenotype acute leukemia: a case report.
Front Oncol
August 2025
Department Hematopathology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
Background: Mixed-phenotype acute leukemia (MPAL) is a rare acute leukemia for which data are currently not available to guide therapy. It has a poor outcome, particularly in elderly patients.
Case Presentation: We report the successful use of venetoclax/azacitidine as treatment for a treatment-naive elderly patient with early T-cell precursor (ETP)/myeloid MPAL.
A Rare Case of F-FDG-avid Renomegaly as the Initial Presentation of Acute Lymphoblastic Leukemia.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Acute lymphoblastic leukaemia (ALL) is a prevalent cause of paediatric leukaemia. Patients with ALL typically exhibit symptoms such as fever, bleeding, weight loss, and bone pain. Blood investigations results predominantly show anaemia and pancytopenia with blast cells in the peripheral smear.
View Article and Find Full Text PDFThe Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.
Am J Hematol
September 2025
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking.
View Article and Find Full Text PDFIvermecatin induces cytotoxic effects in SUP-B15 cell line.
Turk J Pediatr
September 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Background: Glucocorticoids remain the primary treatment for acute lymphoblastic leukemia (ALL) in children. However, glucocorticoid-resistant ALL exhibits increased mortality rates. To overcome resistance and improve management strategies, alternative therapeutic agents are required.
View Article and Find Full Text PDF